HOME >> MEDICINE >> NEWS
Integrative Cancer Therapies journal accepted into prestigious ISI index

tice or Exercise Intervention? Studying the Benefit for Cancer Survivors"

"Extraction-Dependent Effects of American Ginseng (Panax quinquifolium) on Human Breast Cancer Cell Proliferation and Estrogen Receptor Activation"

Preadministration of High-Dose Salicylates, Suppressors of NF-kB Activation, May Increase the Chemosensitivity of Many Cancers

"Integrative cancer treatment incorporates the best of conventional interventions with meaningful, complementary therapies, and individualizes each patient's care regimen. Treatment plans may include chemotherapy, chronomodulated chemotherapy (circadian-timed chemotherapy), prescriptive exercise, nutritional pharmacology, scientifically tailored supplements, mind/body work and physical therapy," Dr. Block explains. "This acknowledgment by ISI will help professionals and patients alike understand ICT is a forum for disseminating information about groundbreaking and forward-looking work and I congratulate our editorial staff, editorial and advisory boards, and contributors to ICT for this important recognition."


'"/>

Contact: Judy Erickson
media.inquiries@sagepub.com
SAGE Publications
25-Sep-2006


Page: 1 2

Related medicine news :

1. Embargoed materials for Complementary & Integrative Medicine Conference
2. American Cancer Society to hold third annual Virtual Relay For Life in Second Life
3. Cancer research summaries
4. Cancer on the agenda of the Portuguese EU Council Presidency
5. Tony Hunter receives Robert. J. and Claire Pasarow Award for Cancer Research
6. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
7. OHSU Cancer Institute, VA researchers find way to identify which men need a second biopsy
8. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival
9. Ireland Cancer Center researcher lays out benefits of aspirin to prevent colon cancer
10. Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma
11. Margaret Foti receives AACR Award for Leadership and Extraordinary Achievements in Cancer Research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... 2016 , ... 10 Best Water is excited to announce a ... owners that topped the list as a result of their commitment to offering clients ... was Tibet 5100, a top notch water company that specializes in providing the public ...
(Date:2/10/2016)... ... February 10, 2016 , ... United ... Nesbitt as the latest addition to its growing list of Partner Firms. ... the Southeast, from Orlando to Huntsville and in between. , Harnessing the experience ...
(Date:2/10/2016)... Boston, Massachusetts (PRWEB) , ... February 10, 2016 ... ... practice models to effectively measure change in their patients. Research shows that the ... traditional methods. To help therapists overcome this challenge and learn more about the ...
(Date:2/10/2016)... ... February 10, 2016 , ... IDEX ... accessories. These PEEK-lined stainless steel (PLS) columns combine the strength of traditional stainless ... the integrity of biological samples while operating at ultra-high pressures of 20,000 psi. ...
(Date:2/10/2016)... ... February 10, 2016 , ... Anxiety of older Americans over ... of Medicare Part D a decade ago, according to The Senior Citizens League ... on how they are coping with rapidly rising costs. “The implications are chilling, ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016  Astellas Pharma Inc. (TSE: ... announced today that it has successfully completed, through its ... offer to purchase all issued and outstanding shares of ... and CEO: Paul Wotton , "Ocata") for a ... in cash ("Tender Offer"). Astellas commenced the Tender Offer ...
(Date:2/10/2016)... Puerto Rico Healthcare and Life Sciences ... and Life Sciences Report 2016 . --> ... Healthcare and Life Sciences Report 2016 . ... territory in the world for pharma manufacturing, a territory with ... and more universities per square mile than anywhere else on ...
(Date:2/10/2016)... Feb. 10, 2016 Mast Therapeutics, Inc. ... clinical-stage therapies for sickle cell disease and heart failure, ... of 29,090,910 units at a price to the public ... share of the Company,s common stock and one warrant ... at an exercise price of $0.42 per share. The ...
Breaking Medicine Technology:
Cached News: